Clinical Trial Update: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. [Phase 2, Phase 3]

View source ↗

Summary

A multicenter, randomized Phase II/III trial comparing ranibizumab plus panretinal photocoagulation to panretinal photocoagulation alone in high-risk proliferat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Association for Innovation and Biomedical Research on Light and Image | Conditions: High Risk Proliferative Diabetic Retinopathy | Phase 2, Phase 3 | Status: COMPLETED